Cancer has been the most common cause of death in Thailand from 2002 (65.4/100,000/year in 2002). With regard to leading cancers in Thailand for female population, the highest incidence falls into cervical cancer (25/100,000/year) followed by breast, liver and bile duct, bronchus and lung, colon and rectum, and ovarian cancer. In 2003, there were 6,243 new cases of cervical cancer with the death of 2,620 women. Therefore, in Thailand, seven women die from cervical cancer each day. However, the incidence of cervical cancer in Thailand is decreasing. The important factor contributed to this decreasing is the implement of Thailand dual-track strategy cervical screening program using both Pap smear and visual inspection with acetic acid (VIA)-cryotherapy. Learning about the epidemiologic data of gynecologic cancer could raise public awareness and play a part in establishing measures for prevention, control and treatment of the cancer which will contribute to the better health of women, and of course, decrease the expense used in various modalities of treatment.
Acetic Acid ; Bile Ducts ; Breast ; Bronchi ; Cause of Death ; Colon ; Female ; Humans ; Incidence ; Learning ; Liver ; Lung ; Mass Screening ; Ovarian Neoplasms ; Rectum ; Thailand ; Uterine Cervical Neoplasms

No abstract available.
Asian Continental Ancestry Group ; Humans

Between the years of 2010–2012, it was estimated there were a total of 112,392 new cases of cancers in Thailand, thus, the total age-standardized rate (ASR) per 100,000 is 137.6. In regards to the most prevalent types of cancer in female, breast cancer has the highest ASR, followed by cervical cancer (ASR=14.4); liver and bile duct cancer; colon and rectum cancer; trachea, bronchus and lung cancer; ovarian cancer (ASR=6.0); thyroid cancer; non-Hodgkin lymphoma and uterine cancer (ASR=4.3). The trend of cervical cancer in Thailand is decreasing, one key factor in making this possible was the employment of dual tract strategy (Pap smear and visual inspection with acetic acid [VIA]) by the government in 2005. In the future, the government is also considering integrating human papillomavirus (HPV) vaccination into the national immunization program, which may assist in the prevention of cervical cancer. By studying the statistical data of gynecologic cancer, it will be possible to formulate measures for the prevention, control and treatment of gynecologic cancer. Eventually, it will potentially improve the quality of life (QoL) of patients as well as decrease the mortality rate caused by gynecologic cancer.
Acetic Acid ; Aged ; Breast Neoplasms/epidemiology/pathology ; Early Detection of Cancer ; Female ; Genital Neoplasms, Female/*epidemiology/prevention & control ; Humans ; Middle Aged ; Papanicolaou Test ; Papillomavirus Infections/prevention & control ; Papillomavirus Vaccines ; Quality of Life ; Thailand/epidemiology ; Uterine Cervical Neoplasms/epidemiology/pathology/prevention & control ; Uterine Neoplasms/epidemiology ; Vaginal Smears

No abstract available.

No abstract available.

OBJECTIVE: The primary objective of this study was to compare quality of life of disease-free patients after therapy for gynecologic malignancies at follow-up in comparison with healthy check-up patients. Our second objective was to assess correlation between demographic data, disease and treatment factors and quality of life scores. METHODS: Patients completed the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life questionnaire at least 6 months after treatment for a gynecologic malignancy. Responses were compared to unmatched healthy women who were seen for standard gynecologic screening examinations. Statistical calculation was done using chi-squared tests, Wilcoxon rank-sum, and Kruskal-Wallis one-way analysis and Spearman rank correlations. Factors associated with FACT-G scores were evaluated using univariate and multivariate analyses. RESULTS: Eight hundred and seventy patients were recruited. The median time since therapy was 61 months (range, 6 to 173 months). The overall FACT-G scores were higher in the patient group than in the healthy group (p<0.05). The scores of each subscale measuring physical, functional, social/family and emotional well-being were also higher in the patient group (p<0.05). Multivariate analysis revealed correlation between Eastern Cooperative Oncology Group performance status, educational level, care giver, presence of economic problems and FACT-G scores. CONCLUSION: The quality of life scores were higher in gynecologic cancer patients after treatment. And the factors that associated with the higher score in the patient group are having husband as a caregiver, no financial problem, Eastern Cooperative Oncology Group score 0 or 1 and having high school or higher education.
Caregivers ; Educational Status ; Female ; Follow-Up Studies ; Humans ; Mass Screening ; Multivariate Analysis ; Quality of Life ; Spouses ; Survivors ; Surveys and Questionnaires

OBJECTIVE: The purpose of this study was to develop a risk prediction score for distinguishing benign ovarian mass from malignant tumors using CA-125, human epididymis protein 4 (HE4), ultrasound findings, and menopausal status. The risk prediction score was compared to the risk of malignancy index and risk of ovarian malignancy algorithm (ROMA). METHODS: This was a prospective, multicenter (n=6) study with patients from six Asian countries. Patients had a pelvic mass upon imaging and were scheduled to undergo surgery. Serum CA-125 and HE4 were measured on preoperative samples, and ultrasound findings were recorded. Regression analysis was performed and a risk prediction model was developed based on the significant factors. A bootstrap technique was applied to assess the validity of the HE4 model. RESULTS: A total of 414 women with a pelvic mass were enrolled in the study, of which 328 had documented ultrasound findings. The risk prediction model that contained HE4, menopausal status, and ultrasound findings exhibited the best performance compared to models with CA-125 alone, or a combination of CA-125 and HE4. This model classified 77.2% of women with ovarian cancer as medium or high risk, and 86% of women with benign disease as very-low, low, or medium-low risk. This model exhibited better sensitivity than ROMA, but ROMA exhibited better specificity. Both models performed better than CA-125 alone. CONCLUSION: Combining ultrasound with HE4 can improve the sensitivity for detecting ovarian cancer compared to other algorithms.
Adult ; *Algorithms ; Biomarkers, Tumor/*blood ; CA-125 Antigen/blood ; Decision Support Techniques ; Diagnosis, Differential ; Female ; Humans ; Menopause ; Middle Aged ; Ovarian Neoplasms/*diagnosis/ultrasonography ; Predictive Value of Tests ; Prospective Studies ; Proteins/*analysis ; ROC Curve ; Risk Assessment/methods ; Sensitivity and Specificity

This workshop was held on July 31-August 1, 2010 and was organized to promote the academic environment and to enhance the communication among Asian countries prior to the 2nd biennial meeting of Australian Society of Gynaecologic Oncologists (ASGO), which will be held on November 3-5, 2011. We summarized the whole contents presented at the workshop. Regarding cervical cancer screening in Asia, particularly in low resource settings, and an update on human papillomavirus (HPV) vaccination was described for prevention and radical surgery overview, fertility sparing and less radical surgery, nerve sparing radical surgery and primary chemoradiotherapy in locally advanced cervical cancer, were discussed for management. As to surgical techniques, nerve sparing radical hysterectomy, optimal staging in early ovarian cancer, laparoscopic radical hysterectomy, one-port surgery and robotic surgery were introduced. After three topics of endometrial cancer, laparoscopic surgery versus open surgery, role of lymphadenectomy and fertility sparing treatment, there was a special additional time for clinical trials in Asia. Finally, chemotherapy including neo-adjuvant chemotherapy, optimal surgical management, and the basis of targeted therapy in ovarian cancer were presented.
Asia ; Asian Continental Ancestry Group ; Chemoradiotherapy ; Endometrial Neoplasms ; Female ; Fertility ; Humans ; Hysterectomy ; Laparoscopy ; Lymph Node Excision ; Mass Screening ; Ovarian Neoplasms ; Uterine Cervical Neoplasms ; Vaccination